Matthias Alder - 01 Oct 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role: Chief Executive Officer, Director
Signature: /s/ Jason Minio, Attorney-in-Fact
Issuer symbol: GANX
Transactions as of: 01 Oct 2023
Net transactions value: $0
Form type: 4
Filing time: 03 Oct 2023, 16:36:35 UTC
Previous filing: 22 Sep 2023
Next filing: 14 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GANX	Common Stock	Options Exercise		+825	+14%		6,675	01 Oct 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GANX	Restricted Stock Units	Options Exercise	$0	-825	-8.3%	$0.000000	9,075	01 Oct 2023	Common Stock	825		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2	The RSUs vested 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.